Bioptic News
News
0
Ticker
6850.TWO
ISIN
TW0006850001
Actualités Eulerpool Bioptic
Actualités de l'action Bioptic
Bioptic est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant Bioptic.
Communiqués de presse relatifs à l'action Bioptic
Bioptic publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.
Bioptic News 2026
Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action Bioptic (6850.TWO, ISIN : TW0006850001). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez Bioptic.
Bioptic Action
Bioptic BiOptic Inc generates revenue through the sale of capillary electrophoresis instruments, including the Qsep100, Qsep1, and Qsep400 series, which are used for biomolecule separation and detection. The company also sells related consumables such as S1, S2, S3, F3 cassettes for DNA fragment analysis, R1 and NR1 cassettes for RNA detection, P2 cassettes for protein analysis, and Q series for quantitative detection. Additionally, BiOptic Inc offers reagents including polymerase chain reaction reagents, veterinary medicine-related reagents, human gene detection reagents, and food-related reagents. These products are primarily sold to customers in China, Hong Kong, and Taiwan, with the company focusing on the healthcare and research sectors. The firm's main customer segments include laboratories, hospitals, and research institutions that require advanced detection equipment and consumables for genetic and molecular analysis. BiOptic Inc's product portfolio targets both human and veterinary medical applications, as well as food safety testing, indicating a diversified market approach. The company's focus on high-precision instruments and specialized reagents positions it to serve clients needing reliable solutions for nucleic acid and protein analysis. BiOptic Inc's revenue streams are derived from direct sales of its instruments, cassettes, and reagents to end-users in the healthcare and research sectors. The company's products are designed for specific applications, such as DNA, RNA, and protein detection, which drives demand from specialized laboratories and medical facilities. By offering a comprehensive range of products, BiOptic Inc ensures that its customers can access all necessary tools for their molecular analysis needs within a single supplier.